This Lung Cancer Awareness Month, the Alliance for Clinical Trials in Oncology—a National Cancer Institute -sponsored national network spanning 26,000 cancer specialists across North America—is highlighting seven active, potentially practice-changing clinical trials targeting critical gaps across the cancer care continuum:
- Attacking Early-Stage Recurrence: High-profile phase III trials like ACCIO (led by Dr. Jacob Sands, Dana-Farber, Boston) and AASI-NSCLC (led by Dr. Muhammad Furqan, Univ. of Oklahoma) are moving immunotherapies (pembrolizumab and atezolizumab) directly into earlier surgical settings, aiming to stop relapse before it starts.
The Shift to Adjuvant Immunotherapy: Why oncologists are testing the use of powerful immunotherapies that use the body’s own immune system to fight disease before surgery.
- Precision Radiation for Residual Disease: The phase II I²-PORT trial (led by Dr. David Kozono, Mass General Brigham, Boston) and Dr. Jeremy Brownstein, Ohio State) is evaluating highly targeted radiation to destroy stubborn lymph node disease after chemo-immunotherapy while sparing healthy tissue.
- Tackling Rare & Difficult Cancers: A phase II study testing dual immunotherapy (nivolumab + ipilimumab) to shrink aggressive tumors before surgery in sarcomatoid mesothelioma (led by Dr. Aaron Mansfield, Mayo Clinic, Rochester, Minn.).
- Groundbreaking studies validating multicancer early-detection blood tests (Dr. Marie Wood, Univ. of Colorado), chatbot-enabled at-home genetic screening for young adults (Dr. Angela Bradbury, Abramson Cancer Center, Philadelphia).
Remember, more than 80% of lung cancer is caused by smoking. If you smoke: stop, and participate in early detection programs. Even with many advances, the five year survival rate remains under 30%.
